发明名称 |
LIPIDOMIC BIOMARKERS |
摘要 |
Lipidomic markers for Hepatitis C and related conditions, treat hepatic fibrosis and hepatocellular carcinoma. An agent administered to such subject may be an cellular total fatty-acid content under iminosugar, which may be effective against hepatitis C. Such iminosugar may be, for example, one of N-substituted deoxynojrimycins and pharmaceutically acceptable salts thereof, N-substituted deoxygalactonojirimycins and pharmaceutically acceptable salts thereof and N-substituted Me-deoxygalactonojirimycins and pharmaceutically acceptable salts thereof. A method of assessing a Hepatitis C infection or a condition caused by or associated with said infection. This method comprises: obtaining a biological sample from a subject in need thereof; determining a level of at least one Hepatitis C lipidomic biomarker in said biological sample; and comparing said level of with a control level of said Hepatitis C lipidomic biomarker to assess the Hepatitis C infection or the condition caused by or associated with said infection in the subject. |
申请公布号 |
EP2991657(A4) |
申请公布日期 |
2017.02.22 |
申请号 |
EP20140791918 |
申请日期 |
2014.04.30 |
申请人 |
The Chancellor, Masters and Scholars of The University of Oxford;United Therapeutics Corporation |
发明人 |
LAING, Peter;DWEK, Raymond;POLLOCK, Stephanie;ZITZMANN, Nicole |
分类号 |
A01N43/40;A61K31/445;A61K31/45 |
主分类号 |
A01N43/40 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|